Immunotherapy for Renal Cell Carcinoma
Joint Authors
Itsumi, Momoe
Tatsugami, Katsunori
Source
Clinical and Developmental Immunology
Issue
Vol. 2010, Issue 2010 (31 Dec. 2010), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-01-03
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy.
Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials.
Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement.
Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed.
The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.
American Psychological Association (APA)
Itsumi, Momoe& Tatsugami, Katsunori. 2011. Immunotherapy for Renal Cell Carcinoma. Clinical and Developmental Immunology،Vol. 2010, no. 2010, pp.1-8.
https://search.emarefa.net/detail/BIM-460288
Modern Language Association (MLA)
Itsumi, Momoe& Tatsugami, Katsunori. Immunotherapy for Renal Cell Carcinoma. Clinical and Developmental Immunology No. 2010 (2010), pp.1-8.
https://search.emarefa.net/detail/BIM-460288
American Medical Association (AMA)
Itsumi, Momoe& Tatsugami, Katsunori. Immunotherapy for Renal Cell Carcinoma. Clinical and Developmental Immunology. 2011. Vol. 2010, no. 2010, pp.1-8.
https://search.emarefa.net/detail/BIM-460288
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-460288